National coverage of biological materials for translational research in the Danish cancerbiobank (RBGB) and of corresponding clinical data in the Danish Gynecological Cancer Database (DGCD)

Abstract

Objective: Optimal personalized medicine may be based on specific predictive/prognostic biomarkers in order to discern between responders and nonresponders. Knowledge of markers is based on biomarker studies analyzing clinical data and their associated biological materials stored in high-quality biobanks. There is no precise knowledge of the extent of nationwide clinical data and corresponding biological specimens available for translational research in gynecologic cancer diseases in Denmark. The aim was to investigate the coverage of biological materials in the Bio- and GenomeBank, Denmark (RBGB), for patients with primary ovarian cancer (tubal, peritoneal, and ovarian) registered in the nationwide compulsory Danish Gynecological Cancer Database (DGCD) for the period 2015–2018.